Cobra continues to develop robust and scalable process strategies for virus manufacturing and production, with media development and optimisation (animal component free), and adaptation to suspension-based growth.
We have a platform process in place for adenovirus and have experience with different AAV processes to support our viral vaccine and gene therapy
customer requirements. Cobra has also developed processes for viruses including HSV, lentivirus, and a variety of oncolytic viruses.
To improve the quality and productivity of customers’ virus products, Cobra has developed closed processing systems to maximise transfection efficiency and harvest parameters.
Cobra can optimise multiplicity and point of infection (MOI and POI), has developed efficient extraction and primary recovery procedures, and utilises low pressure chromatographic purification methods.